Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.

MLA

Dieudonné, A., et al. “Prevalent Breast Cancer Patients with a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users.” Breast Cancer Research & Treatment, vol. 118, no. 3, Dec. 2009, pp. 531–38. EBSCOhost, https://doi.org/10.1007/s10549-009-0463-5.

APA

Dieudonné, A., Lambrechts, D., Claes, B., Vandorpe, T., Wildiers, H., Timmerman, D., Billen, J., Leunen, K., Amant, F., Berteloot, P., Smeets, A., Paridaens, R., Weltens, C., Limbergen, E., Bogaert, W., Vergote, I., Huffel, S., Christiaens, M., & Neven, P. (2009). Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Research & Treatment, 118(3), 531–538. https://doi.org/10.1007/s10549-009-0463-5

Chicago

Dieudonné, A., D. Lambrechts, B. Claes, T. Vandorpe, H. Wildiers, D. Timmerman, J. Billen, et al. 2009. “Prevalent Breast Cancer Patients with a Homozygous Mutant Status for CYP2D6*4: Response and Biomarkers in Tamoxifen Users.” Breast Cancer Research & Treatment 118 (3): 531–38. doi:10.1007/s10549-009-0463-5.